Capricor Therapeutics Inc

CAPRNASDAQ · USD
7.59USD0.00 (+0.80%)
1210

Capricor Therapeutics Inc (CAPR) Covered Calls

Capricor Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 91.67%, high versus the past year. CAPR's highest covered call setup is the $22.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 192.16% out of the money with 1 day to expiration, a 196.15% return until expiration, and a 71,594.29% theoretical annualized return. Across the setups shown, annualized returns run from 19,486.06% to 71,594.29% at strikes between $11.00 and $22.00, with 1 day to expiration, as of Nov 19, 2026.

Read more

Running CAPR covered calls helps you generate income from Capricor Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CAPR covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If CAPR stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CAPR covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CAPR covered call is worth writing.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.

2026-11-20122.00192.160.300.401477.00196.1571594.29-3.98+0.025160.10
2026-11-20120.00165.600.050.501252.00166.2760687.92-0.66+0.031,8250.45
2026-11-20117.00125.760.101.65957.00127.0946388.45-1.33+0.06971.55
2026-11-20115.0099.200.351.20782.00103.8537905.71-4.65+0.103780.85
2026-11-20114.0085.920.252.15672.0089.2432573.71-3.32+0.132291.90
2026-11-20113.5079.280.054.90602.0079.9529180.61-0.66+0.1514.85
2026-11-20113.0072.640.452.20592.0078.6228695.88-5.98+0.171381.75
2026-11-20112.0059.360.501.35497.0066.0024090.97-6.64+0.214260.85
2026-11-20111.0046.080.901.45437.0058.0321182.60-11.95+0.276050.55
2026-11-20111.5052.720.052.90402.0053.3919486.06-0.66+0.24262.85

As of Nov 19, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank91.67% High
  • Market cap (M$)441
  • 52 weeks high-81.20%
  • 52 weeks low156.42%
  • Analyst recommendationBuy
    1.89
  • Target price$27.25
    259.03% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-10
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.65
  • EPS growth next 5 years45.29%

As of Nov 20, 2026